Advertisement

Neurobiology and Pharmacological Prevention of Suicide in Mood Disorders

  • Xenia Gonda
  • Zoltan Rihmer
  • Peter Dome
Chapter

Abstract

Suicide is a complex and multicausal human behaviour, and because of these characteristics, understanding and delineating its neurobiological background is challenging. In spite of a vast array of suicide studies applying different approaches, we are still far away from understanding suicide in its complexity and integrating the already acquired knowledge into a comprehensive model on suicidal behaviour. This would however highly aid the development of pharmacological agents to prevent suicide especially in the framework of affective episodes in mood disorder patients. In the first part of the chapter, our already existing knowledge concerning the neurobiological background of suicide will be overviewed, while in the second part, we summarise the most relevant findings concerning pharmacological prevention of suicide in mood disorders.

Keywords

Prefrontal Cortex Suicide Attempt Suicidal Behaviour Mood Stabiliser Lithium Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ahrens B, Muller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001;34(4):132–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Akiskal HS, Benazzi F. Psychopathologic correlates of suicidal ideation in major depressive outpatients: is it all due to unrecognized (bipolar) depressive mixed states? Psychopathology. 2005;38(5):273–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Alvarez JC, Cremniter D, Lesieur P, Gregoire A, Gilton A, Macquin-Mavier I, Jarreau C, Spreux-Varoquaux O. Low blood cholesterol and low platelet serotonin levels in violent suicide attempters. Biol Psychiatry. 1999;45(8):1066–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord. 2002;68(2–3):167–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC, Merikangas KR. Major depressive disorder with subthreshold bipolarity in the national comorbidity survey replication. Am J Psychiatry. 2010;167(10):1194–201.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Arango V, Ernsberger P, Sved AF, Mann JJ. Quantitative autoradiography of alpha 1- and alpha 2-adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res. 1993;630(1–2):271–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, Chen JJ, Mann JJ. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2001;25(6):892–903.CrossRefGoogle Scholar
  8. 8.
    Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res. 1995;688(1–2):121–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Arango V, Underwood MD, Mann JJ. Alterations in monoamine receptors in the brain of suicide victims. J Clin Psychopharmacol. 1992;12(2 Suppl):8S–12.PubMedGoogle Scholar
  10. 10.
    Arango V, Underwood MD, Mann JJ. Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Biol Psychiatry. 1996;39(2):112–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Arranz B, Cowburn R, Eriksson A, Vestling M, Marcusson J. Gamma-aminobutyric acid-B (GABAB) binding sites in postmortem suicide brains. Neuropsychobiology. 1992;26(1–2):33–6.PubMedGoogle Scholar
  12. 12.
    Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J. Brain 5-HT1A, 5-HT1D, and 5-HT2 receptors in suicide victims. Biol Psychiatry. 1994;35(7):457–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry. 1976;33(10):1193–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Austin MC, Whitehead RE, Edgar CL, Janosky JE, Lewis DA. Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience. 2002;114(3):807–15.CrossRefPubMedGoogle Scholar
  15. 15.
    Baca-Garcia E, Diaz-Sastre C, Basurte E, Prieto R, Ceverino A, Saiz-Ruiz J, de Leon J. A prospective study of the paradoxical relationship between impulsivity and lethality of suicide attempts. J Clin Psychiatry. 2001;62(7):560–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Bach-Mizrachi H, Underwood MD, Kassir SA, Bakalian MJ, Sibille E, Tamir H, Mann JJ, Arango V. Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphe nuclei: major depression and suicide. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2006;31(4):814–24.CrossRefGoogle Scholar
  17. 17.
    Baldessarini RJ, Hennen J. Genetics of suicide: an overview. Harv Rev Psychiatry. 2004;12(1):1–13.PubMedGoogle Scholar
  18. 18.
    Baldessarini RJ, Undurraga J, Vázquez GH, Tondo L, Salvatore P, Ha K, Khalsa HM, Lepri B, Ha TH, Chang JS, Tohen M, Vieta E. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand. 2012;125:293–302.CrossRefPubMedGoogle Scholar
  19. 19.
    Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006;8:625–39.CrossRefPubMedGoogle Scholar
  20. 20.
    Bielau H, Steiner J, Mawrin C, Trubner K, Brisch R, Meyer-Lotz G, Brodhun M, Dobrowolny H, Baumann B, Gos T, Bernstein HG, Bogerts B. Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann N Y Acad Sci. 2007;1096:157–69.CrossRefPubMedGoogle Scholar
  21. 21.
    Boldrini R, Devito R, Diomedi-Camassei F, Francalanci P, Inserra A, Boglino C, Donfrancesco A, Jenkner A, Callea F. Pulmonary blastomas of childhood: histologic, immunohistochemical, ultrastructural aspects and therapeutic considerations. Ultrastruct Pathol. 2005;29(6):493–501.CrossRefPubMedGoogle Scholar
  22. 22.
    Bonkale WL, Murdock S, Janosky JE, Austin MC. Normal levels of tryptophan hydroxylase immunoreactivity in the dorsal raphe of depressed suicide victims. J Neurochem. 2004;88(4):958–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry. 2000;157(12):1925–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR, Horton RW. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res. 1997;769(1):135–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Bowden CL. Pharmacological treatment of bipolar disorder: a review. In: Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N, editors. Bipolar disorder. Chichester: Wiley; 2002. p. 191–221.CrossRefGoogle Scholar
  26. 26.
    Brent DA, Bridge J, Johnson BA, Connolly J. Suicidal behavior runs in families. A controlled family study of adolescent suicide victims. Arch Gen Psychiatry. 1996;53(12):1145–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Brent DA, Melhem N. Familial transmission of suicidal behavior. Psychiatry Clin N Am. 2008;31(2):157.CrossRefGoogle Scholar
  28. 28.
    Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res. 1979;1(2):131–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Callado LF, Meana JJ, Grijalba B, Pazos A, Sastre M, Garcia-Sevilla JA. Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem. 1998;70(3):1114–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Cheetham SC, Crompton MR, Katona CL, Horton RW. Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res. 1988;443(1–2):272–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Cheetham SC, Crompton MR, Katona CL, Horton RW. Brain 5-HT1 binding sites in depressed suicides. Psychopharmacology. 1990;102(4):544–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Cheetham SC, Crompton MR, Katona CL, Parker SJ, Horton RW. Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res. 1988;460(1):114–23.CrossRefPubMedGoogle Scholar
  33. 33.
    Coryell W, Schlesser M. The dexamethasone suppression test and suicide prediction. Am J Psychiatry. 2001;158(5):748–53.CrossRefPubMedGoogle Scholar
  34. 34.
    Coryell W, Young EA. Clinical predictors of suicide in primary major depressive disorder. J Clin Psychiatry. 2005;66(4):412–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Costanza A, D’Orta I, Perroud N, Burkhardt S, Malafosse A, Mangin P, La Harpe R. Neurobiology of suicide: do biomarkers exist? Int J Legal Med. 2014;128:73–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Cougnard A, Verdoux H, Grolleau A, Moride Y, Begaud B, Tournier M. Impact of antidepressants on the risk of suicide in patients with depression in real-life conditions: a decision analysis model. Psychol Med. 2009;39(8):1307–15.CrossRefPubMedGoogle Scholar
  37. 37.
    Courtet P, Gottesman II, Jollant F, Gould TD. The neuroscience of suicidal behaviors: what can we expect from endophenotype strategies? Transl Psychiatry. 2011;1:e7.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Currier D, Mann JJ. Stress, genes and the biology of suicidal behavior. Psychiatr Clin N Am. 2008;31(2):247–69.CrossRefGoogle Scholar
  39. 39.
    De Berardis D, Conti CM, Serroni N, Moschetta FS, Carano A, Salerno RM, Cavuto M, Farina B, Alessandrini M, Janiri L, Pozzi G, Di Giannantonio M. The role of cholesterol levels in mood disorders and suicide. J Biol Regul Homeost Agents. 2009;23(3):133–40.PubMedGoogle Scholar
  40. 40.
    de Leo D, Heller T. Social modeling in the transmission of suicidality. Crisis. 2008;29(1):11–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Dumais A, Lesage AD, Alda M, Rouleau G, Dumont M, Chawky N, Roy M, Mann JJ, Benkelfat C, Turecki G. Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry. 2005;162(11):2116–24.CrossRefPubMedGoogle Scholar
  42. 42.
    Dwivedi Y, Conley RR, Roberts RC, Tamminga CA, Pandey GN. [(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims. Am J Psychiatry. 2002;159(1):66–73.CrossRefPubMedGoogle Scholar
  43. 43.
    Dwivedi Y, Rao JS, Rizavi HS, Kotowski J, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60(3):273–82.CrossRefPubMedGoogle Scholar
  44. 44.
    Dwivedi Y, Rizavi HS, Shukla PK, Lyons J, Faludi G, Palkovits M, Sarosi A, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol Psychiatry. 2004;55(3):234–43.CrossRefPubMedGoogle Scholar
  45. 45.
    Egeland JA, Sussex JN. Suicide and family loading for affective disorders. JAMA J Am Med Assoc. 1985;254(7):915–8.CrossRefGoogle Scholar
  46. 46.
    Ellison LF, Morrison HI. Low serum cholesterol concentration and risk of suicide. Epidemiology. 2001;12(2):168–72.CrossRefPubMedGoogle Scholar
  47. 47.
    Ernst C, Deleva V, Deng X, Sequeira A, Pomarenski A, Klempan T, Ernst N, Quirion R, Gratton A, Szyf M, Turecki G. Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers. Arch Gen Psychiatry. 2009;66(1):22–32.CrossRefPubMedGoogle Scholar
  48. 48.
    Ernst C, Mechawar N, Turecki G. Suicide neurobiology. Prog Neurobiol. 2009;89(4):315–33.CrossRefPubMedGoogle Scholar
  49. 49.
    Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha(2A)-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2004;29(8):1512–21.CrossRefGoogle Scholar
  50. 50.
    Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330(7488):396.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry. 2011;168(1):40–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Freed WJ, Dillon-Carter O, Kleinman JE. Properties of [3H]AMPA binding in postmortem human brain from psychotic subjects and controls: increases in caudate nucleus associated with suicide. Exp Neurol. 1993;121(1):48–56.CrossRefPubMedGoogle Scholar
  53. 53.
    Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–45.CrossRefPubMedGoogle Scholar
  54. 54.
    Furczyk K, Schutova B, Michel TM, Thome J, Buttner A. The neurobiology of suicide – a review of post-mortem studies. J Mol Psychiatry. 2013;1(1):2.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Galfalvy H, Zalsman G, Huang YY, Murphy L, Rosoklija G, Dwork AJ, Haghighi F, Arango V, Mann JJ. A pilot genome wide association and gene expression array study of suicide with and without major depression. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2013;14(8):574–82.CrossRefGoogle Scholar
  56. 56.
    Garcia-Sevilla JA, Escriba PV, Ozaita A, La Harpe R, Walzer C, Eytan A, Guimon J. Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem. 1999;72(1):282–91.CrossRefPubMedGoogle Scholar
  57. 57.
    Garland M, Hickey D, Corvin A, Golden J, Fitzpatrick P, Cunningham S, Walsh N. Total serum cholesterol in relation to psychological correlates in parasuicide. Br J Psychiatry. 2000;177:77–83.Google Scholar
  58. 58.
    Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69:580–7.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164(9):1356–63.CrossRefPubMedGoogle Scholar
  60. 60.
    Glowinski AL, Bucholz KK, Nelson EC, Fu Q, Madden PA, Reich W, Heath AC. Suicide attempts in an adolescent female twin sample. J Am Acad Child Adolesc Psychiatry. 2001;40(11):1300–7.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Golier JA, Marzuk PM, Leon AC, Weiner C, Tardiff K. Low serum cholesterol level and attempted suicide. Am J Psychiatry. 1995;152(3):419–23.CrossRefPubMedGoogle Scholar
  62. 62.
    Gonda X, Fountoulakis KN, Harro J, Pompili M, Akiskal HS, Bagdy G, Rihmer Z. The possible contributory role of the S allele of 5-HTTLPR in the emergence of suicidality. J Psychopharmacol. 2011;25(7):857–66.CrossRefPubMedGoogle Scholar
  63. 63.
    Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ, Garcia-Sevilla JA, Guimon J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors. Mol Psychiatry. 2002;7(7):755–67.CrossRefPubMedGoogle Scholar
  64. 64.
    Gonzalez AM, Pascual J, Meana JJ, Barturen F, del Arco C, Pazos A, Garcia-Sevilla JA. Autoradiographic demonstration of increased alpha 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J Neurochem. 1994;63(1):256–65.CrossRefPubMedGoogle Scholar
  65. 65.
    Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA J Am Med Assoc. 2003;290(11):1467–73.CrossRefGoogle Scholar
  66. 66.
    Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 1990.Google Scholar
  67. 67.
    Gross-Isseroff R, Dillon KA, Fieldust SJ, Biegon A. Autoradiographic analysis of alpha 1-noradrenergic receptors in the human brain postmortem. Effect of suicide. Arch Gen Psychiatry. 1990;47(11):1049–53.CrossRefPubMedGoogle Scholar
  68. 68.
    Gross-Isseroff R, Weizman A, Fieldust SJ, Israeli M, Biegon A. Unaltered alpha(2)-noradrenergic/imidazoline receptors in suicide victims: a postmortem brain autoradiographic analysis. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2000;10(4):265–71.CrossRefGoogle Scholar
  69. 69.
    Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68(3):380–3.CrossRefPubMedGoogle Scholar
  70. 70.
    Hiroi N, Wong ML, Licinio J, Park C, Young M, Gold PW, Chrousos GP, Bornstein SR. Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls. Mol Psychiatry. 2001;6(5):540–6.CrossRefPubMedGoogle Scholar
  71. 71.
    Holemans S, De Paermentier F, Horton RW, Crompton MR, Katona CL, Maloteaux JM. NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res. 1993;616(1–2):138–43.CrossRefPubMedGoogle Scholar
  72. 72.
    Isometsa ET, Lonnqvist JK. Suicide attempts preceding completed suicide. Br J Psychiatry J Ment Sci. 1998;173:531–5.CrossRefGoogle Scholar
  73. 73.
    Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338–43.CrossRefPubMedGoogle Scholar
  74. 74.
    Jokinen J, Nordstrom AL, Nordstrom P. ROC analysis of dexamethasone suppression test threshold in suicide prediction after attempted suicide. J Affect Disord. 2008;106(1–2):145–52.CrossRefPubMedGoogle Scholar
  75. 75.
    Jokinen J, Nordstrom P. HPA axis hyperactivity as suicide predictor in elderly mood disorder inpatients. Psychoneuroendocrinology. 2008;33(10):1387–93.CrossRefPubMedGoogle Scholar
  76. 76.
    Jollant F, Lawrence NL, Olie E, Guillaume S, Courtet P. The suicidal mind and brain: a review of neuropsychological and neuroimaging studies. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2011;12(5):319–39.CrossRefGoogle Scholar
  77. 77.
    Kaplan JR, Shively CA, Fontenot MB, Morgan TM, Howell SM, Manuck SB, Muldoon MF, Mann JJ. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys. Psychosom Med. 1994;56:479–84.CrossRefPubMedGoogle Scholar
  78. 78.
    Kapusta ND, Mossaheb N, Etzersdorfer E, Hlavin G, Thau K, Willeit M, Praschak-Rieder N, Sonneck G, Leithner-Dziubas K. Lithium in drinking water and suicide mortality. Br J Psychiatry. 2011;198:346–50.CrossRefPubMedGoogle Scholar
  79. 79.
    Keilp JG, Sackeim HA, Brodsky BS, Oquendo MA, Malone KM, Mann JJ. Neuropsychological dysfunction in depressed suicide attempters. Am J Psychiatry. 2001;158(5):735–41.CrossRefPubMedGoogle Scholar
  80. 80.
    Kendler KS. Decision making in the pathway from genes to psychiatric and substance use disorders. Mol Psychiatry. 2013;18(6):640–5.CrossRefPubMedGoogle Scholar
  81. 81.
    Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry. 2005;62(8):860–6.CrossRefPubMedGoogle Scholar
  82. 82.
    Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160(4):790–2.CrossRefPubMedGoogle Scholar
  83. 83.
    Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the food and drug administration database. Int J Neuropsychopharmacol. 2001;4(2):113–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the food and drug administration database. Arch Gen Psychiatry. 2000;57(4):311–7.CrossRefPubMedGoogle Scholar
  85. 85.
    Kim CD, Seguin M, Therrien N, Riopel G, Chawky N, Lesage AD, Turecki G. Familial aggregation of suicidal behavior: a family study of male suicide completers from the general population. Am J Psychiatry. 2005;162(5):1017–9.CrossRefPubMedGoogle Scholar
  86. 86.
    Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genomics. 2007;8:413.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Klempan TA, Sequeira A, Canetti L, Lalovic A, Ernst C, ffrench-Mullen J, Turecki G. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry. 2009;14(2):175–89.CrossRefPubMedGoogle Scholar
  88. 88.
    Korpi ER, Kleinman JE, Wyatt RJ. GABA concentrations in forebrain areas of suicide victims. Biol Psychiatry. 1988;23(2):109–14.CrossRefPubMedGoogle Scholar
  89. 89.
    Kraus JE, Horrigan JP, Carpenter DJ, Fong R, Barrett PS, Davies JT. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. J Affect Disord. 2010;120(1–3):40–7.CrossRefPubMedGoogle Scholar
  90. 90.
    Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002;20(2):171–5.CrossRefPubMedGoogle Scholar
  91. 91.
    Kunugi H, Takei N, Aoki H, Nanko S. Low serum cholesterol in suicide attempters. Biol Psychiatry. 1997;41(2):196–200.CrossRefPubMedGoogle Scholar
  92. 92.
    Laje G, Allen AS, Akula N, Manji H, John Rush A, McMahon FJ. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics. 2009;19(9):666–74.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Le-Niculescu H, Levey DF, Ayalew M, Palmer L, Gavrin LM, Jain N, Winiger E, Bhosrekar S, Shankar G, Radel M, Bellanger E, Duckworth H, Olesek K, Vergo J, Schweitzer R, Yard M, Ballew A, Shekhar A, Sandusky GE, Schork NJ, Kurian SM, Salomon DR, Niculescu 3rd AB. Discovery and validation of blood biomarkers for suicidality. Mol Psychiatry. 2013;18(12):1249–64.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Leon AC, Keller MB, Warshaw MG, Mueller TI, Solomon DA, Coryell W, Endicott J. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry. 1999;156(2):195–201.PubMedGoogle Scholar
  95. 95.
    Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal-fluid of suicidal individuals – a meta-analysis. Pharmacopsychiatry. 1995;28(2):45–50.CrossRefPubMedGoogle Scholar
  96. 96.
    Lester D. Serum cholesterol levels and suicide: a meta-analysis. Suicide Life Threat Behav. 2002;32(3):333–46.CrossRefPubMedGoogle Scholar
  97. 97.
    Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Bjorkqvist M, Traskman-Bendz L, Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66(3):287–92.CrossRefPubMedGoogle Scholar
  98. 98.
    Ludwig J, Marcotte DE. Anti-depressants, suicide, and drug regulation. J Policy Anal Manag J Assoc Publ Policy Anal Manag. 2005;24(2):249–72.CrossRefGoogle Scholar
  99. 99.
    Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. Am J Psychiatry. 2002;159(6):909–16.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci. 2003;4(10):819–28.CrossRefPubMedGoogle Scholar
  101. 101.
    Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2001;24(5):467–77.CrossRefGoogle Scholar
  102. 102.
    Mann JJ, Henteleff RA, Lagattuta TF, Perper JA, Li S, Arango V. Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites. J Neural Transm. 1996;103(11):1337–50.CrossRefPubMedGoogle Scholar
  103. 103.
    Matsubara S, Arora RC, Meltzer HY. Serotonergic measures in suicide brain: 5-HT1A binding sites in frontal cortex of suicide victims. J Neural Transm Gen Sect. 1991;85(3):181–94.CrossRefPubMedGoogle Scholar
  104. 104.
    McGirr A, Paris J, Lesage A, Renaud J, Turecki G. Risk factors for suicide completion in borderline personality disorder: a case-control study of cluster B comorbidity and impulsive aggression. J Clin Psychiatry. 2007;68(5):721–9.CrossRefPubMedGoogle Scholar
  105. 105.
    McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonte B, Szyf M, Turecki G, Meaney MJ. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12(3):342–8.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    McGowan PO, Sasaki A, Huang TC, Unterberger A, Suderman M, Ernst C, Meaney MJ, Turecki G, Szyf M. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. PLoS ONE. 2008;3(5):e2085.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Meana JJ, Barturen F, Garcia-Sevilla JA. Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry. 1992;31(5):471–90.CrossRefPubMedGoogle Scholar
  108. 108.
    Menke A, Domschke K, Czamara D, Klengel T, Hennings J, Lucae S, Baune BT, Arolt V, Muller-Myhsok B, Holsboer F, Binder EB. Genome-wide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2012;37(3):797–807.CrossRefGoogle Scholar
  109. 109.
    Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci Off J Soc Neurosci. 2004;24(6):1478–85.CrossRefGoogle Scholar
  110. 110.
    Modai I, Valevski A, Dror S, Weizman A. Serum cholesterol levels and suicidal tendencies in psychiatric inpatients. J Clin Psychiatry. 1994;55(6):252–4.PubMedGoogle Scholar
  111. 111.
    Monkul ES, Hatch JP, Nicoletti MA, Spence S, Brambilla P, Lacerda AL, Sassi RB, Mallinger AG, Keshavan MS, Soares JC. Fronto-limbic brain structures in suicidal and non-suicidal female patients with major depressive disorder. Mol Psychiatry. 2007;12(4):360–6.CrossRefPubMedGoogle Scholar
  112. 112.
    Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ. 2001;322(7277):11–5.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Mullins N, Perroud N, Uher R, Butler AW, Cohen-Woods S, Rivera M, Malki K, Euesden J, Power RA, Tansey KE, Jones L, Jones I, Craddock N, Owen MJ, Korszun A, Gill M, Mors O, Preisig M, Maier W, Rietschel M, Rice JP, Muller-Myhsok B, Binder EB, Lucae S, Ising M, Craig IW, Farmer AE, McGuffin P, Breen G, Lewis CM. Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: a genome-wide association and polygenic scoring study. Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2014;165B(5):428–37.CrossRefGoogle Scholar
  114. 114.
    Mundo E, Cattaneo E, Russo M, Altamura AC. Clinical variables related to antidepressant-induced mania in bipolar disorder. J Affect Disord. 2006;92:227–30.CrossRefPubMedGoogle Scholar
  115. 115.
    Must A, Koks S, Vasar E, Tasa G, Lang A, Maron E, Vali M. Common variations in 4p locus are related to male completed suicide. Neruomol Med. 2009;11(1):13–9.CrossRefGoogle Scholar
  116. 116.
    Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Multiple risk factor intervention trial research group. Arch Intern Med. 1992;152(7):1490–500.CrossRefPubMedGoogle Scholar
  117. 117.
    Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry. 1988;45(6):577–9.CrossRefPubMedGoogle Scholar
  118. 118.
    Noga JT, Hyde TM, Herman MM, Spurney CF, Bigelow LB, Weinberger DR, Kleinman JE. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse. 1997;27(3):168–76.CrossRefPubMedGoogle Scholar
  119. 119.
    Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 1995;675(1–2):157–64.CrossRefPubMedGoogle Scholar
  120. 120.
    Nowak G, Szewczyk B, Sadlik K, Piekoszewski W, Trela F, Florek E, Pilc A. Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Pol J Pharmacol. 2003;55(3):455–9.PubMedGoogle Scholar
  121. 121.
    O’Leary D, Paykel E, Todd C, Vardulaki K. Suicide in primary affective disorders revisited: a systematic review by treatment era. J Clin Psychiatry. 2001;62(10):804–11.CrossRefPubMedGoogle Scholar
  122. 122.
    Ohgami H, Terao T, Shiotsuki I, Ishii N, Iwata N. Lithium levels in drinking water and risk of suicide. Br J Psychiatry. 2009;194:464–5.CrossRefPubMedGoogle Scholar
  123. 123.
    Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatry Clin N Am. 2000;23(1):11.CrossRefGoogle Scholar
  124. 124.
    Oquendo MA, Placidi GP, Malone KM, Campbell C, Keilp J, Brodsky B, Kegeles LS, Cooper TB, Parsey RV, van Heertum RL, Mann JJ. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Arch Gen Psychiatry. 2003;60(1):14–22.CrossRefPubMedGoogle Scholar
  125. 125.
    Ordway GA. Pathophysiology of the locus coeruleus in suicide. Ann N Y Acad Sci. 1997;836:233–52.CrossRefPubMedGoogle Scholar
  126. 126.
    Pacchiarotti I, Valenti M, Colom F, Rosa AR, Nivoli AM, Murru A, Sanchez-Moreno J, Vieta E. Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord. 2011;129(1–3):321–6.CrossRefPubMedGoogle Scholar
  127. 127.
    Palmer AM, Burns MA, Arango V, Mann JJ. Similar effects of glycine, zinc and an oxidizing agent on [3H]dizocilpine binding to the N-methyl-D-aspartate receptor in neocortical tissue from suicide victims and controls. J Neural Transm Gen Sect. 1994;96(1):1–8.CrossRefPubMedGoogle Scholar
  128. 128.
    Pandey CM, Dwivedi Y. Monoamine receptors and signal transduction mechanisms in suicide. Curr Psychiatr Rev. 2006;2:51–75.CrossRefGoogle Scholar
  129. 129.
    Pandey GN. Biological basis of suicide and suicidal behavior. Bipolar Disord. 2013;15(5):524–41.CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Mondal AC, Shukla PK, Conley RR. Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2005;30(8):1548–56.CrossRefGoogle Scholar
  131. 131.
    Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Conley RR. Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain study. Arch Gen Psychiatry. 2004;61(7):685–93.CrossRefPubMedGoogle Scholar
  132. 132.
    Pandey GN, Dwivedi Y, Rizavi HS, Ren XG, Pandey SC, Pesold C, Roberts RC, Conley RR, Tamminga CA. Higher expression of serotonin 5-HT2A receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry. 2002;159(3):419–29.CrossRefPubMedGoogle Scholar
  133. 133.
    Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, Conley RR, Dwivedi Y. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res. 2012;46(1):57–63.CrossRefPubMedGoogle Scholar
  134. 134.
    Partonen T, Haukka J, Virtamo J, Taylor PR, Lonnqvist J. Association of low serum total cholesterol with major depression and suicide. Br J Psychiatry J Ment Sci. 1999;175:259–62.CrossRefGoogle Scholar
  135. 135.
    Perroud N, Uher R, Ng MY, Guipponi M, Hauser J, Henigsberg N, Maier W, Mors O, Gennarelli M, Rietschel M, Souery D, Dernovsek MZ, Stamp AS, Lathrop M, Farmer A, Breen G, Aitchison KJ, Lewis CM, Craig IW, McGuffin P. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. 2012;12(1):68–77.CrossRefPubMedGoogle Scholar
  136. 136.
    Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci CMLS. 2003;60(6):1158–71.CrossRefPubMedGoogle Scholar
  137. 137.
    Pirkis J, Burgess P. Suicide and recency of health care contacts. A systematic review. Br J Psychiatry. 1998;173:462–74.CrossRefPubMedGoogle Scholar
  138. 138.
    Poulter MO, Du L, Weaver IC, Palkovits M, Faludi G, Merali Z, Szyf M, Anisman H. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol Psychiatry. 2008;64(8):645–52.CrossRefPubMedGoogle Scholar
  139. 139.
    Preti A. Animal model and neurobiology of suicide. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(4):818–30.CrossRefGoogle Scholar
  140. 140.
    Rajkowska G, O’Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2007;32(2):471–82.CrossRefGoogle Scholar
  141. 141.
    Reeves RR, Ladner ME. Antidepressant-induced suicidality. CNS Neurosci Ther. 2010;16:227–33.PubMedGoogle Scholar
  142. 142.
    Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord. 2006;94(1–3):3–13.CrossRefPubMedGoogle Scholar
  143. 143.
    Rihmer Z, Gonda X. Antidepressant-resistant depression: the role of underlying bipolarity. Depression Res Treat. 2011;2011:906462.Google Scholar
  144. 144.
    Rouillon F, Serrurier D, Miller HD, Gerard MJ. Prophylactic efficacy of maprotiline on unipolar depression relapse. J Clin Psychiatry. 1991;52(10):423–31.PubMedGoogle Scholar
  145. 145.
    Roy A, Sarchiopone M, Carli V. Gene-environment interaction and suicidal behavior. J Psychiatr Pract. 2009;15(4):282–8.CrossRefPubMedGoogle Scholar
  146. 146.
    Roy A, Segal NL, Centerwall BS, Robinette CD. Suicide in twins. Arch Gen Psychiatry. 1991;48(1):29–32.CrossRefPubMedGoogle Scholar
  147. 147.
    Roy A, Segal NL, Sarchiapone M. Attempted suicide among living co-twins of twin suicide victims. Am J Psychiatry. 1995;152(7):1075–6.CrossRefPubMedGoogle Scholar
  148. 148.
    Salvi V, Fagiolini A, Swartz HA, Maina G, Frank E. The use of antidepressants in bipolar disorder. J Clin Psychiatry. 2008;69:1307–18.CrossRefPubMedGoogle Scholar
  149. 149.
    Schosser A, Butler AW, Ising M, Perroud N, Uher R, Ng MY, Cohen-Woods S, Craddock N, Owen MJ, Korszun A, Jones L, Jones I, Gill M, Rice JP, Maier W, Mors O, Rietschel M, Lucae S, Binder EB, Preisig M, Perry J, Tozzi F, Muglia P, Aitchison KJ, Breen G, Craig IW, Farmer AE, Muller-Myhsok B, McGuffin P, Lewis CM. Genomewide association scan of suicidal thoughts and behaviour in major depression. PLoS ONE. 2011;6(7):e20690.CrossRefPubMedPubMedCentralGoogle Scholar
  150. 150.
    Secunda SK, Cross CK, Koslow S, Katz MM, Kocsis J, Maas JW, Landis H. Biochemistry and suicidal behavior in depressed patients. Biol Psychiatry. 1986;21(8–9):756–67.CrossRefPubMedGoogle Scholar
  151. 151.
    Secunda SK, Cross CK, Koslow S, Katz MM, Kocsis JH, Maas JW. Studies of amine metabolites in depressed patients. Relationship to suicidal behavior. Ann N Y Acad Sci. 1986;487:231–42.CrossRefPubMedGoogle Scholar
  152. 152.
    Sequeira A, Klempan T, Canetti L, ffrench-Mullen J, Benkelfat C, Rouleau GA, Turecki G. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry. 2007;12(7):640–55.CrossRefPubMedGoogle Scholar
  153. 153.
    Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, Rehal S, Klempan T, Gratton A, Benkelfat C, Rouleau GA, Mechawar N, Turecki G. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS ONE. 2009;4(8):e6585.CrossRefPubMedPubMedCentralGoogle Scholar
  154. 154.
    Sibille E, Arango V, Galfalvy HC, Pavlidis P, Erraji-Benchekroun L, Ellis SP, John Mann J. Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2004;29(2):351–61.CrossRefGoogle Scholar
  155. 155.
    Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72(2):156–67.CrossRefPubMedGoogle Scholar
  156. 156.
    Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41–7.CrossRefPubMedGoogle Scholar
  157. 157.
    Sokolowski M, Wasserman J, Wasserman D. Genome-wide association studies of suicidal behaviors: a review. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2014;24(10):1567–77.CrossRefGoogle Scholar
  158. 158.
    Sokolowski M, Wasserman J, Wasserman D. An overview of the neurobiology of suicidal behaviors as one meta-system. Mol Psychiatry. 2015;20(1):56–71.CrossRefPubMedGoogle Scholar
  159. 159.
    Sondergard L, Lopez AG, Andersen PK, Kessing LV. Continued antidepressant treatment and suicide in patients with depressive disorder. Arch Suicide Res. 2007;11(2):163–75.CrossRefPubMedGoogle Scholar
  160. 160.
    Sondergard L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008;10:87–94.CrossRefPubMedGoogle Scholar
  161. 161.
    Søndergård L1, Kvist K, Andersen PK, Kessing LV. Do antidepressants precipitate youth suicide?: a nationwide pharmacoepidemiological study. Eur Child Adolesc Psychiatry. 2006;15(4):232–40.Google Scholar
  162. 162.
    Statham DJ, Heath AC, Madden PA, Bucholz KK, Bierut L, Dinwiddie SH, Slutske WS, Dunne MP, Martin NG. Suicidal behaviour: an epidemiological and genetic study. Psychol Med. 1998;28(4):839–55.CrossRefPubMedGoogle Scholar
  163. 163.
    Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1997;16(2):162–73.CrossRefGoogle Scholar
  164. 164.
    Stocks GM, Cheetham SC, Crompton MR, Katona CL, Horton RW. Benzodiazepine binding sites in amygdala and hippocampus of depressed suicide victims. J Affect Disord. 1990;18(1):11–5.CrossRefPubMedGoogle Scholar
  165. 165.
    Sundman-Eriksson I, Allard P. [(3)H]Tiagabine binding to GABA transporter-1 (GAT-1) in suicidal depression. J Affect Disord. 2002;71(1–3):29–33.CrossRefPubMedGoogle Scholar
  166. 166.
    Syed A, Chatfield M, Matthews F, Harrison P, Brayne C, Esiri MM. Depression in the elderly: pathological study of raphe and locus ceruleus. Neuropathol Appl Neurobiol. 2005;31(4):405–13.CrossRefPubMedGoogle Scholar
  167. 167.
    Thalmeier A, Dickmann M, Giegling I, Schneider B, A MH, Maurer K, Schnabel A, Kauert G, Moller HJ, Rujescu D. Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 2008;11(2):217–228.Google Scholar
  168. 168.
    Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry. 1996;29:103–7.CrossRefPubMedGoogle Scholar
  169. 169.
    Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006;63(12):1358–67.CrossRefPubMedGoogle Scholar
  170. 170.
    Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K, Schnabel A, Moller HJ, Chen HH, Postolache TT. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand. 2008;117(3):198–206.CrossRefPubMedGoogle Scholar
  171. 171.
    Turecki G. Dissecting the suicide phenotype: the role of impulsive-aggressive behaviours. J Psychiatry Neurosci JPN. 2005;30(6):398–408.PubMedGoogle Scholar
  172. 172.
    Turecki G. The molecular bases of the suicidal brain. Nat Rev Neurosci. 2014;15(12):802–16.CrossRefPubMedGoogle Scholar
  173. 173.
    Underwood MD, Khaibulina AA, Ellis SP, Moran A, Rice PM, Mann JJ, Arango V. Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. Biol Psychiatry. 1999;46(4):473–83.CrossRefPubMedGoogle Scholar
  174. 174.
    Valenstein M, Kim HM, Ganoczy D, Eisenberg D, Pfeiffer PN, Downing K, Hoggatt K, Ilgen M, Austin KL, Zivin K, Blow FC, McCarthy JF. Antidepressant agents and suicide death among US Department of Veterans Affairs patients in depression treatment. J Clin Psychopharmacol. 2012;32(3):346–53.CrossRefPubMedPubMedCentralGoogle Scholar
  175. 175.
    Valenti M, Pacchiarotti I, Rosa AR, Bonnin CM, Popovic D, Nivoli AM, Murru A, Grande I, Colom F, Vieta E. Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disord. 2011;13(2):145–54.CrossRefPubMedGoogle Scholar
  176. 176.
    Valtonen HM, Suominen K, Mantere O, Leppamaki S, Arvilommi P, Isometsa E. Suicidal behaviour during different phases of bipolar disorder. J Affect Disord. 2007;97(1–3):101–7.CrossRefPubMedGoogle Scholar
  177. 177.
    Van Heeringen K, Bijttebier S, Desmyter S, Vervaet M, Baeken C. Is there a neuroanatomical basis of the vulnerability to suicidal behavior? A coordinate-based meta-analysis of structural and functional MRI studies. Front Hum Neurosci. 2014;22(8):824.Google Scholar
  178. 178.
    van Heeringen K, Bijttebier S, Desmyter S, Vervaet M, Baeken C. Is there a neuroanatomical basis of the vulnerability to suicidal behavior? A coordinate-based meta-analysis of structural and functional MRI studies. Front Hum Neurosci. 2014;8:1–8.Google Scholar
  179. 179.
    Vineis P, Pearce NE. Genome-wide association studies may be misinterpreted: genes versus heritability. Carcinogenesis. 2011;32(9):1295–8.CrossRefPubMedGoogle Scholar
  180. 180.
    Virkkunen M. Serum cholesterol in antisocial personality. Neuropsychobiology. 1979;5(1):27–30.CrossRefPubMedGoogle Scholar
  181. 181.
    Voracek M, Loibl LM. Genetics of suicide: a systematic review of twin studies. Wien Klin Wochenschr. 2007;119(15–16):463–75.CrossRefPubMedGoogle Scholar
  182. 182.
    Wagner G, Koch K, Schachtzabel C, Schultz CC, Sauer H, Schlosser RG. Structural brain alterations in patients with major depressive disorder and high risk for suicide: evidence for a distinct neurobiological entity? NeuroImage. 2011;54(2):1607–14.CrossRefPubMedGoogle Scholar
  183. 183.
    Wender PH, Kety SS, Rosenthal D, Schulsinger F, Ortmann J, Lunde I. Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry. 1986;43(10):923–9.CrossRefPubMedGoogle Scholar
  184. 184.
    Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363(9418):1341–5.CrossRefPubMedGoogle Scholar
  185. 185.
    Williams J, Crane C, Barnhofer T, Duggan D. Psychology and suicidal behavior: elaborating the entrapment model. In: Hawton K, editor. Suicide and suicidal behavior: from science to practice. Oxford: Oxford University Press; 2005. p. 71–90.CrossRefGoogle Scholar
  186. 186.
    Willour VL, Seifuddin F, Mahon PB, Jancic D, Pirooznia M, Steele J, Schweizer B, Goes FS, Mondimore FM, Mackinnon DF, Bipolar Genome Study C, Perlis RH, Lee PH, Huang J, Kelsoe JR, Shilling PD, Rietschel M, Nothen M, Cichon S, Gurling H, Purcell S, Smoller JW, Craddock N, DePaulo Jr JR, Schulze TG, McMahon FJ, Zandi PP, Potash JB. A genome-wide association study of attempted suicide. Mol Psychiatry. 2012;17(4):433–44.CrossRefPubMedGoogle Scholar
  187. 187.
    Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–55.CrossRefPubMedGoogle Scholar
  188. 188.
    Yerevanian BI, Koek RJ, Feusner JD, Hwang S, Mintz J. Antidepressants and suicidal behaviour in unipolar depression. Acta Psychiatr Scand. 2004;110(6):452–8.CrossRefPubMedGoogle Scholar
  189. 189.
    Yerevanian BI, Koek RJ, Mintz J. Lithium, anticonvulsants and suicidal behavior in bipolar disorder. J Affect Disord. 2003;73:223–8.CrossRefPubMedGoogle Scholar
  190. 190.
    Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior part 3: impact of antipsychotics. J Affect Disord. 2007;103(1–3):23–8.CrossRefPubMedGoogle Scholar
  191. 191.
    Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior. Part I: lithium, divalproex and carbamazepine. J Affect Disord. 2007;103(1–3):5–11.CrossRefPubMedGoogle Scholar
  192. 192.
    Yerevanian BI, Koek RJ, Mintz J, Akiskal HS. Bipolar pharmacotherapy and suicidal behavior Part 2. The impact of antidepressants. J Affect Disord. 2007;103(1–3):13–21.CrossRefPubMedGoogle Scholar
  193. 193.
    Zhu H, Karolewicz B, Nail E, Stockmeier CA, Szebeni K, Ordway GA. Normal [3H]flunitrazepam binding to GABAA receptors in the locus coeruleus in major depression and suicide. Brain Res. 2006;1125(1):138–46.CrossRefPubMedPubMedCentralGoogle Scholar
  194. 194.
    Zimmermann P, Bruckl T, Nocon A, Pfister H, Lieb R, Wittchen HU, Holsboer F, Angst J. Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry. 2009;66(12):1341–52.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of Psychiatry and PsychotherapySemmelweis UniversityBudapestHungary
  2. 2.Laboratory of Suicide Research and PreventionNational Institute for Psychiatry and AddictologyBudapestHungary

Personalised recommendations